that found<\/a> psilocybin\u2014the primary psychedelic substance produced by mushrooms\u2014was effective at treating major depressive disorder when combined with psychotherapy in adults.<\/p>\nTwo-thirds of clinical trial participants treated with psilocybin-assisted therapy were in \u201ccomplete remission\u201d from their depression after five years, as well as a self-reported lasting improvement across a range of wellbeing measurements.<\/p>\n
\u201cWe found that 67% were in remission at five years compared to 58% at one year,\u201d said study lead author Professor Alan Davis, from Ohio State University, said:<\/p>\n
\u201cWe also saw that across the board, anxiety, depression, global functioning, self-reported depression, all of these measures were showing the same signal of continued improvement up to five years later.\u201d<\/p>\n
Davis co-led the 2021 study\u2014when two participant groups, one receiving treatment right away and another on a wait-list treatment condition, received two doses of psilocybin combined with around 13 hours of psychotherapy.<\/p>\n
\u201cFive years later, most people continued to view this treatment as safe, meaningful, important, and something that catalyzed an ongoing betterment of their life. I think this is a sign that regardless of what the outcomes are, their lives were improved because they participated in something like this,\u201d he said.<\/p>\n
Of the 24 participants, 18 enrolled in the five-year follow-up, which consisted of a range of online questionnaires assessing depression, anxiety, and functional impairment; a clinician-administered depression rating; and interviews.<\/p>\n
When analyzing data at the five-year time point, the researchers assumed the very worst in order to avoid inflating their findings, and considered everyone who didn\u2019t participate in the follow-up to have experienced complete relapse and had returned to their pre-treatment levels of functioning.<\/p>\n
\u201cEven controlling for those baseline estimates from the people who didn\u2019t participate in the long-term follow-up, we still see a very large and significant reduction in depression symptoms,\u201d said Professor Davis. \u201cThat was really exciting for us because this showed that the number of participants still in complete remission from their depression had gone up slightly.\u201d<\/p>\n
Only three participants in the follow-up had reported receiving no depression-related treatment since the trial. Others reported taking antidepressant medications, trying psychedelics or ketamine treatment, or undergoing psychotherapy.<\/p>\n
Before the psilocybin-assisted therapy, the patients lived with debilitating depression that interfered with their capacity to engage in life. But, after the trial, many described perceiving depression as \u201cmore situational and manageable.\u201d<\/p>\n
SCIENCE AND PSYCHEDELICS:<\/p>\n
\u201cThey believed that overall, they had greater capacity for positive emotions and enthusiasm, regardless of whether their depression came back or not,\u201d Davis clarified. \u201cA lot of folks reported that these shifts led to important changes in how they related to their experiences of depression.\u201d<\/p>\n
A few of the people who had tried psychedelics on their own in the intervening years reported that the experiences were not as helpful because of the lack of a clinical support framework.<\/p>\n
The follow-up results, published in the Journal of Psychedelic Studies, showed that, at the five-year time point, 11 participants reported no adverse effects since the clinical trial, while 3 said they were unprepared for the heightened state of emotional sensitivity brought on by psilocybin.<\/p>\n
Acknowledging the study sample is small, Davis said there is still a lot to learn\u2014but that this first look at the durability of the effects of psilocybin-assisted therapy offers a glimpse at the potential lasting positive effects of the treatment.<\/p>\n
The follow-up results were published Sept. 4 in the\u00a0Journal of Psychedelic Studies<\/a>.<\/p>\nSHARE The News About These Robust And Durable Psychiatric Effects From Psilocybin\u2026\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"GNN graphic \u2013 credits, Psilocybe ovoideocystidiata CC 4.0. BY-SA Alan Rockefeller Patients with clinical depression and treated with…\n","protected":false},"author":2,"featured_media":148540,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[1232,49,48,6319,84,393,394,79148,9081,66,19970],"class_list":{"0":"post-148539","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-mental-health","8":"tag-anxiety","9":"tag-ca","10":"tag-canada","11":"tag-depression","12":"tag-health","13":"tag-mental-health","14":"tag-mentalhealth","15":"tag-mushrooms","16":"tag-psychedelics","17":"tag-science","18":"tag-therapy"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/148539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=148539"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/148539\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/148540"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=148539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=148539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=148539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2025\/09\/GNN-graphic-credits-Psilocybe-ovoideocystidiata-CC-4.0.-BY-SA-Alan-Rockefeller-1024x592.jpg\")
GNN graphic \u2013 credits, Psilocybe ovoideocystidiata CC 4.0. BY-SA Alan Rockefeller<\/p>\n